Michael Sagner

As a clinician, Dr. Sagner has spearheaded interventions in the field of endocrinology and cardiometabolic prevention such as the use of GLP1 agonists in Europe. He is the current editor-in-chief of Progress in Preventive Medicine, a peer reviewed journal for P4 medicine--a new approach that is predictive, preventive, personalized and participatory, known as P4--and systems biology-based prevention.

He works on the convergence of systems biology and consumer-driven healthcare to transform medicine from its current reactive approach to P4 medicine, which the journal Future Medicine describes as systems-level approach that will “will make disease care radically more cost effective by personalizing care to each person’s unique biology and by treating the causes rather than the symptoms of disease.” As a public health expert, he has spearheaded several international initiatives in the field of systems biology-driven preventive medicine working with governments and NGOs. 

One of his interests is closing the gap between clinical practice and public health to promote more effective and patient-oriented care and preventive interventions. For that he has collaborated with many NGOs such as the World Heart Federation (WHF), the World Obesity Federation, and the World Health Organization (WHO), where he established the ‘cell to community’ approach in prevention, which maintains that addressing lifestyle-related diseases at the individual level can have vast public health ramifications. 

Read more: Visit European Society of Preventive Medicine (ESPREVMED)